Drug Trial Radar · NCT07266155
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Dec 30, 2027
Study completion May 1, 2028
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an extension study for patients who have completed a prior P10-LP005-02 clinical study. The aim of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of LP-005 injection in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
LP-005 InjectionBiological
IV infusion, Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.